Fulvestrant: pharmacokinetics and pharmacology (Q35750083)

10 August 2017

3 references

18 June 2019

13 November 2019

17 November 2019

Fulvestrant: pharmacokinetics and pharmacology (English)

1 reference

10 August 2017

1 reference

13 November 2019

1 reference

17 November 2019

1 reference

17 November 2019

1 reference

J F R Robertson

1

1 reference

10 August 2017

M Harrison

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 March 2004

4 references

British Journal of Cancer

10 August 2017

18 June 2019

13 November 2019

17 November 2019

4 references

10 August 2017

18 June 2019

13 November 2019

17 November 2019

90 Suppl 1

1 reference

10 August 2017

page(s)

S7-10

1 reference

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

10 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750771

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750771

The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750771

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750771

Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750771

Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750771

Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750771

Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750771

Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin

15 November 2018

1 reference

12 December 2020

ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen

1 reference

12 December 2020

Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes

1 reference

12 December 2020

Back to basics. Administering i.m. injections the right way

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6601630

1 reference

10 August 2017

1 reference

10 August 2017

1 reference